Eli Lilly is to settle more than 18 000 product liability claims against its lead product, the anti-psychotic drug Zyprexa (olanzapine) for schizophrenia and manic depression. The lawsuits mainly revolve around a warning linking the drug with diabetes not being adequately displayed in the package insert.
Related Results
Injectable ZyprexaZyprexa WarningZyprexa filingZyprexa unveiledTexas depresses Zypr…
A U.S. District Court upheld the patent held by Eli Lilly & Co. on olanzapine (Zyprexa), an antipsychotic drug that accounts for about one-third of Lilly’s revenue; net sales in the United States were $2.4 bill…
Lilly added strong warnings to the label of Zyprexa, its best-selling medicine for schizophrenia, Oct. 5, citing the drug’s tendency to cause weight gain, high blood sugar, high cholesterol and other metabolic problems.
For the first time, Zyprexa’s label now acknowledges that …
FDA is examining whether Eli Lilly & Company provided it with accurate data about the side effects of the antipsychotic drug Zyprexa, a potent medicine that has been linked to weight gain and diabetes, “The New York Ti…
Lilly settled an additional 900 product liability lawsuits involving its top-selling drug, the anti-psychotic Zyprexa.
Lilly has settled roughly 28,500 product liability claims involving Zyprexa over the past two years. In June 2005, the company settled 8,000 claims for $690 million. This past January, it settled more than 18…
